Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Should You Buy?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) gapped up prior to trading on Wednesday . The stock had previously closed at $14.5595, but opened at $16.54. Ono Pharmaceutical shares last traded at $16.54, with a volume of 108 shares.

Analyst Ratings Changes

Separately, Zacks Research upgraded Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Ono Pharmaceutical currently has an average rating of “Strong Buy”.

Ono Pharmaceutical Trading Up 13.6%

The firm has a market cap of $7.77 billion, a P/E ratio of 15.75 and a beta of 0.33. The stock has a 50 day simple moving average of $14.65 and a 200-day simple moving average of $14.81. The company has a current ratio of 3.28, a quick ratio of 2.56 and a debt-to-equity ratio of 0.08.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.